Ruiwen Zhang da Robert L. Boblitt daga Jami'ar Houston sun kirkiro wani sabon maganin ciwon daji na pancreatic. The research was published in the Journal of Cancer Research. The drug targets two genes at the same time, and this breakthrough achievement is of great significance for the treatment of aggressive and deadly ciwon cizon sauro.
Ana kuma sa ran wannan magani ya zama tsari na samar da magunguna don magance wasu nau'ikan cutar kansa ko wasu cututtuka. Ciwon kanji yana faruwa lokacin da ƙwayoyin pancreatic suka fara yawaita daga iko kuma suka zama dunqulewa, kuma sakamakon kwayar cutar kanjamau zata iya mamaye wasu sassan jiki. Yawancin cututtukan daji suna farawa ne a cikin yanki na pancreas wanda ke samar da enzymes masu narkewa. Kwayar cututtukan sun hada da ciwon baya ko ciwon ciki, rashin nauyi mara nauyi, da jaundice (launin ruwan dorawa). In addition, a person’s urine may appear dark yellow and itchy skin. There are two oncogenes associated with pancreatic cancer. There are two main ways for the drug to inhibit pancreatic cancer. They activate the nuclear factor of T cell 1 (NFAT1) and murine double microparticle 2 (MDM2), respectively. The latter gene regulates a tumo suppressor gene called p53. When there is no tumor suppressor p53, MDM2 can cause cancer. NFAT1 is used to up-regulate the expression of MDM2, thereby promoting tumor growth. Factors related to diet, nutrition and the environment can lead to increased levels of these factors in the cell.
Lokacin da yake magana game da wannan binciken, Dr. Zhang ya ce har yanzu ba a sadu da bukatun asibiti ba na sababbin magunguna masu inganci da aminci don maganin cutar sankarau. Abubuwan da muka gano suna wakiltar babban ci gaba ne a binciken cutar kansa. Ya kara da cewa: “Mafi yawan kwayoyi suna ta’allaka ne da abu daya. Mun gano wani fili wanda ke nufin kwayoyin halittu guda biyu masu nasaba da cutar kansa. “Sabon maganin wani sinadarin roba ne na MA242. Magungunan na iya cinye sunadarai guda biyu a lokaci guda, don inganta ingantaccen ƙwayar cuta.
